ABSTRACT
Declaration de liens d'interets: Les auteurs n'ont pas precise leurs eventuels liens d'interets.Copyright © 2022
ABSTRACT
Introduction: The MSGo Programme is a patient support platform (PSP) designed for patients commencing on multiple sclerosis disease modifying therapies (DMTs) provided by Novartis. The PSP is delivered through RxMx, a digital health company. The technology aims to connect patients and doctors, improve patient safety and create real-time insights with the support of nurses to assist patient navigation. The patient apps feature tailored functions, including medication reminders, appointment scheduling and educational materials. The nurses work directly with patients to address DMT issues and questions, in order to promote engagement and adherence. The patient app also includes a care partner function, to enable a caretaker to monitor from their own device. Objective(s): The rapidly changing landscape of DMTs, pharmacovigilance and COVID-19 has added challenges to DMT prescreening, onboarding and ongoing support of patients, with many clinics being restricted on physical attendance. The patient app, paired with the HCP and care partner function, aims to keep patients on track with their DMTs and appointments whilst maintaining active communication with their healthcare team. Aim(s): A recent study of MS Nurse care in Australia found that for 5% of participants the PSP services offered across all DMTs was their sole source of support. The aim is to explore the effectiveness of MSGo, a PSP which has evolved since the COVID-19 pandemic as a resource of support, information and communication for both the patient and treating MS team. Method(s): Patients utilising the MSGo app were sent voluntary surveys every 3 months, to ascertain effectiveness of the programme (phone, app or email) since enrolling. Result(s): There are 1200+ patients actively enrolled within the programme. An average patient satisfaction score of 9/10 was recorded for all questions, which covered various aspects of the PSP including DMT initiation, virtual support, at home support and nursing support. The full results of the survey will be presented. Conclusion(s): Patient survey responses indicate that MSGo has been an effective PSP and demonstrates an ongoing need for patients to be supported during their DMT journey, particularly in situations where the PSP nurses are the sole source of support.
ABSTRACT
The world is passing a terrible time while lives are despairing due to coronavirus. In Covid-19, most of the patients suffer from low oxygen saturation. Different types of devices are used to increase the oxygen level. This paper discusses a helmet-based Continuous Positive Airway Pressure (CPAP) device's design and implementation. A blower generates positive pressure, while a pressure sensor adjusts the required pressure. A TFT display is used to monitor the data, and two rotary encoders are used to set the required value. Two Arduino boards are used as real-time and user interface controllers. The hardware simulations and PCB designs are done in the Proteus software. The mechanical body of the CPAP device was designed in Solidworks software. A helmet is connected to the CPAP, also designed in the Solidworks software. The oxygen mixed pressurized air goes through the pipe to the helmet. Finally, the cost of the device is also presented in this paper. © 2021 IEEE.
ABSTRACT
Introduction Pour éviter la propagation du virus lors de la pandémie du COVID-19, un confinement était imposé. Pendant cette période, les patients atteints de maladies chroniques, tel que le diabète, ont eu des difficultés à l’accès aux soins. L’objectif de cette étude est d’évaluer le retentissement de la période de confinement sur la prise en charge des patients diabétiques et sur leur qualité de vie. Patients et méthodes Il s’agit d’une étude descriptive transversale, réalisée au service d’endocrinologie CHU Farhat Hached de Sousse et au Centre de santé de base Bouhssina, sur 3 mois (février mars avril 2020) (après le premier confinement en Tunisie). Résultats On a interrogé 100 patients diabétiques avec une prédominance féminine (66 %). L’âge moyen était de 56,2±5,6 ans. Pendant le confinement, 69 % des patients n’ont pas pu accéder aux soins, 62 % ont déjà raté un RDV, 20 % des patients n’ont pas pu accéder aux médicaments, 57 % avaient des mesures de glycémie plus élevées et 60 % des patients sentaient plus à risque à cause du diabète. Le score de la qualité de vie était au-dessus de la moyenne sur le plan mental chez 20 % et sur le plan physique chez 14 % des patients interrogés. Conclusion Le diabète est connu être associé à des formes graves de COVID-19, ce qui rend ces patients plus vulnérables. Vu la situation sanitaire un accompagnement plus rapproché parait nécessaire basé sur le développement de la télémédecine.